Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell CarcinomaWenxin Xu, Maneka Puligandla, Judith Manola, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|February 5, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2Joseph I Clark, Brendan Curti, Elizabeth J Davis, et al.
Journal for Immunotherapy of Cancer|December 20, 2017
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM<sup>SM</sup> registryBrendan Curti, Gregory A Daniels, David F McDermott, et al.
BJU International|September 4, 2021
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805Jose A Karam, Maneka Puligandla, Keith T Flaherty, et al.
The Journal of Urology|October 10, 2019
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant TrialZiho Lee, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Genitourinary Cancer|July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based ValidationAndres F Correa, Opeyemi Jegede, Naomi B Haas, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyKenneth A Foon, Xiao-Dong Yang, Louis M Weiner, et al.
Journal for Immunotherapy of Cancer|February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionElizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
European Urology|March 12, 2021
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell CarcinomaAndres F Correa, Opeyemi A Jegede, Naomi B Haas, et al.
Pageof 9